Browsing Tag
Capricor Therapeutics Inc.
1 post
Deramiocel’s 9 to 3 FDA panel defeat wipes out half of Capricor’s value before August decision
Capricor loses half its value after a 9 to 3 FDA vote puts deramiocel approval, an $80 million milestone and its launch strategy at risk.